Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 213
- Registration Number
- NCT00508625
Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: placeboDrug: MP-376 (Levofloxacin solution for Inhalation)
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 40
- Registration Number
- NCT00503490
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Phase 2
Completed
- Conditions
- Head and Neck CancerSquamous Cell Carcinoma
- Interventions
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 153
- Registration Number
- NCT00500760
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
Not Applicable
Completed
- Conditions
- HematologyMDSMyelodysplastic SyndromesThrombocytopenia
- Interventions
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 72
- Registration Number
- NCT00472290
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Phase 2
Completed
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 152
- Registration Number
- NCT00467025
Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 3
Completed
- Conditions
- Recurrent and/or Metastatic Head and Neck Cancer
- Interventions
- Drug: ARM 2Drug: ARM 1
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 658
- Registration Number
- NCT00460265
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study
Phase 3
Terminated
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1450
- Registration Number
- NCT00460317
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Completed
- Conditions
- ThrombocytopeniaThrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Idiopathic Thrombocytopenic PurpuraThrombocytopenic Purpura
- Interventions
- Other: Retrospective Chart ReviewOther: Patient-reported Outcome QuestionnairesOther: Physician Survey
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 326
- Registration Number
- NCT00454857
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Phase 2
Completed
- Conditions
- Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 113
- Registration Number
- NCT00454779
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 906
- Registration Number
- NCT00450216
© Copyright 2025. All Rights Reserved by MedPath